Related Experiment Video
Updated: May 17, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.9K
Disease-Modifying Therapies in Parkinson's Disease
Margherita Fabbri1, Jean Christophe Corvol2, Olivier Rascol1
1Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), French NS-Park/F-CRIN Network, University of Toulouse, CHU of Toulouse, INSERM, Toulouse, France.
Neurologic Clinics
|April 4, 2025
Summary
Disease-modifying treatments for Parkinson's disease (PD) aim to slow symptom progression. Current clinical trials targeting alpha-synuclein have yielded disappointing results, but future precision therapies show promise.
Area of Science:
- Neurodegenerative disease research
- Parkinson's disease therapeutics
- Clinical trial analysis
Background:
- Defining disease-modifying treatments as interventions that slow neurodegenerative disease progression.
- Highlighting decades of research into disease-modifying compounds for Parkinson's disease (PD).
Purpose of the Study:
- To provide an overview of recent and ongoing clinical trials for Parkinson's disease (PD).
- To stratify these trials based on their mechanisms of action.
Main Methods:
- Review of current and recent clinical trials for PD disease-modifying therapies.
- Categorization of trials by their targeted mechanisms, including alpha-synuclein and genetic pathways.
Main Results:
- Numerous trials targeting alpha-synuclein have shown disappointing outcomes despite promising preclinical data.
- Anticipation of results from precision trials focusing on genetic populations or specific pathways.
Conclusions:
- Current strategies targeting alpha-synuclein have not yet translated into effective disease modification for PD.
- Future research directions include precision medicine approaches targeting genetic factors like GBA and LRRK2 mutations for PD treatment.
Related Concept Videos
01:24Parkinson's Disease: Treatment
163
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
163
01:15Parkinson's Disease: Overview
360
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
360
01:22Alzheimer's Disease: Treatment
134
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
134
01:28Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32
01:37Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K